Printer Friendly
The Free Library
23,375,127 articles and books


Modest benefit to cognitive function with Avonex. (News).

During the large double-blind placebo-controlled trial of Avonex (interferon beta-1a) that led to FDA approval in 1996, researchers gave cognitive tests to 166 of the participants. All of them had relapsing MS.

A recent analysis of these trial results shows that people who received Avonex did better on some cognitive functions commonly affected by MS.

Participants in the Avonex trial had been given neuropsychological tests at the beginning and end of a 2-year period. The group taking a placebo (or inert injection) showed little or no change. The group taking Avonex showed modest improvement on tests that measured speed of information processing, recent memory, and other functions. These fundings were published in the December 2000 issue of the Annals of Neurology.
COPYRIGHT 2001 National Multiple Sclerosis Society
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Inside MS
Article Type:Product/Service Evaluation
Date:Mar 22, 2001
Words:121
Previous Article:Researchers successfully measure cognitive fatigue in people with MS. (News).
Next Article:Champion chapters rise to a challenge. (National MS Society News).
Topics:



Related Articles
FDA approval sought for Avonex.
FRA approves Avonex for relapsing form of MS.
Conference call helps answer Axonex questions.
MS news at the American Academy of Neurology meeting.
FDA decision on Rebif.
Rebif and Avonex go head-to-head.
Accessing the abcs.
Serono seeks FDA approval for Rebif. (News).
FDA approves Rebif. (News).
Rebif [in context].

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters